Logo     Print Page  Close Window


SEC Filings


10-Q
FIBROCELL SCIENCE, INC. filed this Form 10-Q on 08/09/2018
Entire Document
 

PART I. FINANCIAL INFORMATION
Item 1. Financial Statements.
Fibrocell Science, Inc.
Condensed Consolidated Balance Sheets
(unaudited)
($ in thousands, except share and per share data)

 
June 30,
2018
 
December 31,
2017
Assets
 

 
 

Current assets:
 

 
 

Cash and cash equivalents
$
15,410

 
$
17,417

Prepaid expenses and other current assets
455

 
485

Total current assets
15,865

 
17,902

Property and equipment, net of accumulated depreciation of $2,121 and $1,919, respectively
1,374

 
1,470

Other assets
39

 
39

Total assets
$
17,278

 
$
19,411

 
 
 
 
Liabilities and Stockholders’ Equity
 

 
 

Current liabilities:
 

 
 

Accounts payable
$
635

 
$
862

Related party payable
276

 
2,303

Accrued expenses
1,137

 
1,260

Total current liabilities
2,048

 
4,425

Convertible promissory notes, net of debt discount of $18,003 and $18,003, respectively (see Note 4)

 

Accrued interest payable
1,349

 
967

Warrant liability, long term
747

 
1,073

Derivative liability
2,957

 
3,136

Deferred rent
809

 
803

Total liabilities
7,910

 
10,404

 
 
 
 
Stockholders’ equity:
 

 
 

Preferred stock, $0.001 par value; 5,000,000 shares authorized:
 
 
 
Series A nonredeemable convertible preferred stock; 8,000 shares designated, 8,000 shares issued and outstanding as of June 30, 2018 and December 31, 2017 respectively; aggregate liquidation preference of $8,429 at June 30, 2018

 

Common stock, $0.001 par value; 150,000,000 shares authorized, 7,840,902 and 5,189,755 shares issued and outstanding at June 30, 2018 and December 31, 2017, respectively
8

 
5

Additional paid-in capital
193,958

 
187,805

Accumulated deficit
(184,598
)
 
(178,803
)
Total stockholders’ equity
9,368

 
9,007

Total liabilities and stockholders’ equity
$
17,278

 
$
19,411



The accompanying notes are an integral part of these unaudited condensed consolidated financial statements.


5